Analysis Of Recent Drug Reviews Illuminates Path For Future NDAs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Every month, Pharmaceutical Approvals Monthly dissects a new drug review by FDA. Using FDA’s own review documents, including the discipline reviews, decision memos, meeting minutes, emails, and other documents, we strive to illuminate the agency decision-making process.
You may also be interested in...
Drug Review Documents Hint At Impact Of Broad Changes At FDA
The last year has been a year of dramatic changes at FDA, as the agency implements the sweeping new authorities of the FDA Amendments Act. As industry tries to stay abreast of the new world of FDA, taking a closer look at how some of those changes played out in individual case studies – through the lens of Pharmaceutical Approvals Monthly’s drug review profiles – can yield some valuable lessons for companies preparing for the gauntlet of an FDA review.
FDA, Industry Unveil Mechanistic Trial Simulation Models
FDA partnered with industry to create four trial simulation models for Parkinson's disease, diabetes, depression and measuring cancer progression, which were unveiled at the Jan. 24-25 Drug Industry Association meeting on "Sharing Knowledge To Improve Clinical Drug Development and Regulatory Decisions.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.